Publications by authors named "David Panka"

Claim this Profile
R
Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
David J Panka, Qingjun Liu, Andrew K Geissler, James W Mier

Mol Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Qingjun Liu, James W Mier, David J Panka

Mol Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells.
David J Panka, Wei Wang, Michael B Atkins, James W Mier

Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma.
Daniel C Cho, Matthew B Cohen, David J Panka, Michael Collins, Musie Ghebremichael

Clin Cancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating BRAF Levels Correlate with Treatment in Patients with Thyroid Carcinoma.
Carrie C Lubitz, Tiannan Zhan, Viswanath Gunda, Salma Amin, Benjamin J Gigliotti, David J Panka

Thyroid· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Amy K Erbe, Wei Wang, Jacob Goldberg, Mikayla Gallenberger, KyungMann Kim, David J Panka

Clin Cancer Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
Wei Wang, Amy K Erbe, Mikayla Gallenberger, KyungMann Kim, Lakeesha Carmichael, David Panka

Cancer Immunol Immunother· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Guo Chen, Jennifer L McQuade, David J Panka, Courtney W Hudgens, Ali Amin-Mansour

JAMA Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel drugs that target the metabolic reprogramming in renal cell cancer.
Johannes C van der Mijn, David J Panka, Andrew K Geissler, Henk M Verheul, James W Mier

Cancer Metab· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
Priscilla K Brastianos, Ganesh M Shankar, Corey M Gill, Amaro Taylor-Weiner, Naema Nayyar, David J Panka

J Natl Cancer Inst· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.
Carrie C Lubitz, Sareh Parangi, Tammy M Holm, M Jordana Bernasconi, Aislyn P Schalck, David J Panka

J Mol Diagn· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.
Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, Isabel Ferreiro-Neira, Taylor Hoff, David J Panka

PLoS One· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
David F McDermott, Su-Chun Cheng, Sabina Signoretti, Kim A Margolin, Joseph I Clark, David J Panka

Clin Cancer Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.
David J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, Aislyn P Schalck, Laleh Montaser-Kouhsari

Mol Cancer Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assaying for BRAF V600E in tissue and blood in melanoma.
David J Panka, James W Mier, Ryan J Sullivan

Methods Mol Biol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
David J Panka, Qingjun Liu, Andrew K Geissler, James W Mier

Mol Cancer· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.
Richard W Joseph, Ryan J Sullivan, Robyn Harrell, Katherine Stemke-Hale, David Panka

J Immunother· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Qingjun Liu, James W Mier, David J Panka

Mol Cancer· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
Liang Zhang, Manoj Bhasin, Rachel Schor-Bardach, Xiaoen Wang, Michael P Collins, David Panka

PLoS One· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood.
David J Panka, Ryan J Sullivan, James W Mier

Melanoma Res· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
Daniel C Cho, Matthew B Cohen, David J Panka, Michael Collins, Musie Ghebremichael

Clin Cancer Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
Jeffrey A Sosman, Carole Carrillo, Walter J Urba, Lawrence Flaherty, Michael B Atkins, David J Panka

J Clin Oncol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of melanoma on immune function in the regional lymph node basin.
Benjamin Negin, David Panka, Wei Wang, Mustaqueem Siddiqui, Nicholas Tawa

Clin Cancer Res· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines.
David J Panka, Daniel C Cho, Michael B Atkins, James W Mier

J Biol Chem· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
David J Panka, Michael B Atkins, James W Mier

Clin Cancer Res· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis